{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:13:32Z","timestamp":1770509612377,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,8]],"date-time":"2010-10-08T00:00:00Z","timestamp":1286496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00228-010-0883-5","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T09:25:37Z","timestamp":1286443537000},"page":"47-54","source":"Crossref","is-referenced-by-count":39,"title":["Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?"],"prefix":"10.1007","volume":"67","author":[{"given":"Laura","family":"Magliulo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fallarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Maria","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Biolcati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriella","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,8]]},"reference":[{"issue":"9","key":"883_CR1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(03)00502-7","volume":"2","author":"E Scarpini","year":"2003","unstructured":"Scarpini E, Scheltens P, Feldman H (2003) Treatment of Alzheimer\u2019s disease: current status and new perspectives. Lancet Neurol 2(9):539\u2013547","journal-title":"Lancet Neurol"},{"issue":"1","key":"883_CR2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1345\/aph.17150","volume":"32","author":"EL Barner","year":"1998","unstructured":"Barner EL, Gray SL (1998) Donepezil use in Alzheimer\u2019s disease. Ann Pharmacother 32(1):70\u201377","journal-title":"Ann Pharmacother"},{"issue":"9","key":"883_CR3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","volume":"62","author":"F Varsaldi","year":"2006","unstructured":"Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, Lombardi G (2006) Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer\u2019s disease patients. Eur J Clin Pharmacol 62(9):721\u2013726","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"883_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2125.1998.0460s1025.x","volume":"46","author":"PJ Tiseo","year":"1998","unstructured":"Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Concurrent administration of donepezil HCL and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 46(Suppl 1):25\u201329","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"883_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2125.1998.0460s1030.x","volume":"46","author":"PJ Tiseo","year":"1998","unstructured":"Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Concurrent administration of donepezil HCL and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 46(Suppl 1):30\u201334","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"883_CR6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00228-004-0848-7","volume":"60","author":"A Wang","year":"2005","unstructured":"Wang A, Yu BN, Luo CH, Tan ZR, Zhou G, Wang LS, Zhang W, Li Z, Liu J, Zhou HH (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60(12):843\u2013848","journal-title":"Eur J Clin Pharmacol"},{"key":"883_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Shaik RHN, van der Heiden IP et al (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245\u201354","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"883_CR8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clpt.2004.08.022","volume":"76","author":"DA Hesselink","year":"2004","unstructured":"Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76(6):545\u2013556","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"883_CR9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockm\u00f6ller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):733\u20139","journal-title":"Pharmacogenetics"},{"issue":"10","key":"883_CR10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","volume":"48","author":"RH Schaik van","year":"2002","unstructured":"van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48(10):1668\u20131671","journal-title":"Clin Chem"},{"issue":"1","key":"883_CR11","first-page":"81","volume":"48","author":"K Ishiwata","year":"2007","unstructured":"Ishiwata K, Kawamura K, Yanai K, Hendrikse NH (2007) In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48(1):81\u201387","journal-title":"J Nucl Med"},{"issue":"8","key":"883_CR12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","volume":"13","author":"DL Kroetz","year":"2003","unstructured":"Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG, Pharmacogenetics of Membrane Transporters Investigators (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8):481\u201394","journal-title":"Pharmacogenetics"},{"issue":"2","key":"883_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008571-200103000-00008","volume":"11","author":"S Ito","year":"2001","unstructured":"Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2\/Cmoat, in healthy Japanese subjects. Pharmacogenetics 11(2):175\u201384","journal-title":"Pharmacogenetics"},{"issue":"10","key":"883_CR14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1023\/A:1020433422259","volume":"19","author":"M Horinouchi","year":"2002","unstructured":"Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K (2002) Significant genetic linkage of MDR1 polymorphisms at position 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 19(10):1581\u20135","journal-title":"Pharm Res"},{"issue":"5","key":"883_CR15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mcp.2002.129196","volume":"72","author":"A Johne","year":"2002","unstructured":"Johne A, K\u00f6pke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockm\u00f6ller J, Cascorbi I, Roots I (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72(5):584\u201394","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"883_CR16","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Soc USA 97(7):3473\u20133478","journal-title":"Proc Natl Acad Soc USA"},{"issue":"12","key":"883_CR17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","volume":"58","author":"C Verstuyft","year":"2003","unstructured":"Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58(12):809\u201312","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"883_CR18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1023\/A:1023282312757","volume":"20","author":"Y Morita","year":"2003","unstructured":"Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K (2003) MDR1 genotype related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 20(4):552\u20136","journal-title":"Pharm Res"},{"issue":"1","key":"883_CR19","first-page":"4955","volume":"62","author":"T Illmer","year":"2002","unstructured":"Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Sch\u00e4kel U, Ehninger G, Schaich M (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62(1):4955\u20134962","journal-title":"Cancer Res"},{"issue":"2","key":"883_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70(2):189\u2013199","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"883_CR21","first-page":"3246","volume":"9","author":"RH Mathijssen","year":"2003","unstructured":"Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9(9):3246\u20133253","journal-title":"Clin Cancer Res"},{"issue":"2","key":"883_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","volume":"19","author":"S Ozawa","year":"2004","unstructured":"Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1. Drug Metab Pharmacokinet 19(2):83\u201395","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"883_CR23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"883_CR24","first-page":"669","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12(3):669\u2013677","journal-title":"A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr Res"},{"issue":"2","key":"883_CR25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1570-0232(01)00592-X","volume":"768","author":"N Yasui-Furukori","year":"2002","unstructured":"Yasui-Furukori N, Furuya R, Takahata T, Tateishi T (2002) Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-perfomance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 768(2):261\u2013265","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"9","key":"883_CR26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","volume":"16","author":"RA Mirghani","year":"2006","unstructured":"Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, Eriksen J, Herben VM, Jones BC, Gustafsson LL, Bertilsson L (2006) CYP3A5 genotype has significant effect on quintine 3-hydroxilation in Tanzanians, who have lower total CYP3A activity compared to a Swedish population. Pharmacogenet Genomics 16(9):637\u201345","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"883_CR27","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/clinchem\/46.11.1834","volume":"46","author":"RH Schaik van","year":"2000","unstructured":"van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J (2000) CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46(11):1834\u201336","journal-title":"Clin Chem"},{"issue":"suppl 1","key":"883_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.0460s1001.x","volume":"46","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 46(suppl 1):1\u20136","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"883_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2125.1998.0460s1007.x","volume":"46","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46(suppl 1):7\u201312","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"883_CR30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391","journal-title":"Nat Genet"},{"issue":"10","key":"883_CR31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271\u20131294","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"883_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetics, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496\u2013526","journal-title":"Pharmacol Ther"},{"issue":"1","key":"883_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2005.09.020","volume":"338","author":"C Rodriguez-Antona","year":"2005","unstructured":"Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338(1):299\u2013305","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"883_CR34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2003.12.011","volume":"207","author":"H Dally","year":"2004","unstructured":"Dally H, Bartsch H, J\u00e4ger B, Edler L, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Kayser K, Schulz V, Risch A (2004) Genotype relationship in the CYP3A locus in Caucasians. Cancer Lett 207(1):95\u201399","journal-title":"Cancer Lett"},{"issue":"4","key":"883_CR35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/FTD.0b013e31811f390a","volume":"29","author":"B Sinues","year":"2007","unstructured":"Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B (2007) CYP3A5*3 AND CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Dug Monit 29(4):412\u2013416","journal-title":"Ther Dug Monit"},{"issue":"Suppl 1","key":"883_CR36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2125.2004.01801.x","volume":"58","author":"CF Nagy","year":"2004","unstructured":"Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD (2004) Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharm 58(Suppl 1):25\u201333","journal-title":"Br J Clin Pharm"},{"issue":"2","key":"883_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","volume":"13","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogenetics 13(2):89\u201395","journal-title":"Pharmacogenetics"},{"issue":"2","key":"883_CR38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2002.126177","volume":"72","author":"Y Kurata","year":"2002","unstructured":"Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavaliability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72(2):209\u201319","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"883_CR39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clpt.2005.11.013","volume":"79","author":"J Lamba","year":"2006","unstructured":"Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79(4):325\u2013338","journal-title":"Clin Pharmacol. Ther"},{"issue":"5","key":"883_CR40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181858ca9","volume":"30","author":"A Gunes","year":"2008","unstructured":"Gunes A, Spina E, Dahl M-L, Scordo MG (2008) ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 30(5):628\u2013633","journal-title":"Ther Drug Monit"},{"issue":"1","key":"883_CR41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2000.104391","volume":"67","author":"F Sata","year":"2000","unstructured":"Sata F, Sapone A, Elizondo G, Miller SP, VP ZW, Raunio H, Crespi CL, Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67(1):48\u201356","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"883_CR42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/clinchem\/47.6.1104","volume":"47","author":"RH Schaik van","year":"2001","unstructured":"van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J (2001) The CYP3A4*3 allele: is it really rare? Clin Chem 47(6):1104\u20131106","journal-title":"Clin Chem"},{"issue":"3","key":"883_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorpisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169\u2013174","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0883-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0883-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:12:31Z","timestamp":1636632751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0883-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0883-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,8]]}}}